% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reing:856855,
      author       = {Reßing, Nina and Marquardt, Viktoria and Gertzen,
                      Christoph and Schöler, Andrea and Schramm, Alexander and
                      Kurz, Thomas and Gohlke, Holger and Aigner, Achim and Remke,
                      Marc and Hansen, Finn Kristian},
      title        = {{D}esign, {S}ynthesis and {B}iological {E}valuation of
                      β-{P}eptoid-{C}apped {HDAC} {I}nhibitors with
                      {A}nti-{N}euroblastoma and {A}nti-{G}lioblastoma {A}ctivity},
      journal      = {MedChemComm},
      volume       = {10},
      number       = {7},
      issn         = {2040-2511},
      address      = {Cambridge},
      publisher    = {RSC Publ.},
      reportid     = {FZJ-2018-06194},
      pages        = {1109-1115},
      year         = {2019},
      abstract     = {Histone deacetylases (HDACs) have been identified as
                      promising epigenetic drug targets for the treatment of
                      neuroblastomaand glioblastoma. In this work, we have
                      rationally designed a novel type of peptoid‐based histone
                      deacetylase inhibitors(HDACi). A mini library of
                      β‐peptoid‐capped HDACi was synthesized using a
                      four‐step protocol. All compounds were screenedin
                      biochemical assays for its inhibition of HDAC1 and HDAC6 and
                      docking studies were performed to rationalize the
                      observedselectivity profile. The synthesized compounds were
                      further examined for tumor cell‐inhibitory activity
                      against a panel ofneuroblastoma and glioblastoma cell lines.
                      In particular, non‐selective compounds with potent
                      activity against HDAC1 andHDAC6 showed strong
                      antiproliferative effects. The most promising HDACi,
                      compound 6i, displayed submicromolar tumorcell‐inhibitory
                      potential (IC50: 0.21 – 0.67 μM) against all five cancer
                      cell lines investigated and exceeded the activity of
                      theFDA‐approved HDACi vorinostat.},
      cin          = {JSC / ICS-6 / NIC},
      ddc          = {540},
      cid          = {I:(DE-Juel1)JSC-20090406 / I:(DE-Juel1)ICS-6-20110106 /
                      I:(DE-Juel1)NIC-20090406},
      pnm          = {511 - Computational Science and Mathematical Methods
                      (POF3-511) / Forschergruppe Gohlke $(hkf7_20170501)$},
      pid          = {G:(DE-HGF)POF3-511 / $G:(DE-Juel1)hkf7_20170501$},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000475806000003},
      doi          = {10.1039/C8MD00454D},
      url          = {https://juser.fz-juelich.de/record/856855},
}